PRM85 Validating Approaches to Modelling End-Stage Renal Disease Using The Ims Core Diabetes Model  by McEwan, P et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A697
unlicensed comparator bevacizumab, the frequency and duration of treatment, and 
the extrapolation of visual acuity beyond short-term observed trial data. The trial 
evidence used ranged from 6 months to 3 years and included evidence for treatment 
in one eye only. Most TAs modelled one treated eye only, with crude adjustments 
applied to account for bilateral treatment. Only the most recent appraisal for afliber-
cept in central RVO modelled the visual acuity of both eyes. All other uncertainties 
were consistent throughout the identified TAs. ConClusions: The main uncer-
tainties are in which eye(s) patients are treated in practice and the extrapolation of 
outcomes beyond trial data. Modelling is limited by short-term clinical trial evidence 
that provides evidence for the treatment of one eye only.
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objeCtives: Standard approaches to evaluating the health economic benefit of avoid-
ing hypoglycaemia often attribute a per-event disutility (PED) with growing evidence 
of the diminishing marginal effects (DME) of hypoglycaemia on utility as frequency 
increases. This study compared PED to DME on predicted quality adjusted life expec-
tancy (QALE). Methods: This study used the CORE Diabetes Model (CDM) and pub-
lished audit data for patients with type 1 diabetes switching to insulin degludec (ID) 
from either insulin glargine or detemir (IGD). Mean (± SD) baseline profiles were age 
35.0 years (± 11.4); diabetes duration 18.2 years (± 7.5); HbA1c 9.4% (±0.8); weight 77.0 
kg (±10.7) and 3.9 hypoglycaemia (severe and non-severe) events per week (±0.9). 
Mean change in clinical variables was HbA1c -0.5% (±0.3); weight +0.8g (±1.6) and 
hypoglycaemia events/week -3.6 (±0.9). A baseline cohort was projected over a lifetime 
using the CDM using published PED disutility (-0.0052) and published DME disutility 
(0.0141*[number of events]^0.3393) with and without treatment effects applied to cal-
culate life expectancy (LE) and QALE associated with the pre and post-switch profiles. 
Results were discounted at 3.5%. Results: Overall discounted LE was 18.8 years and 
19.06 years for IGD and ID profiles respectively and discounted QALE (ignoring the 
impact of hypoglycaemia) was 12.13 and 12.4 for IGD and ID respectively. Discounted 
QALE was reduced by 1.85 (IGD) and 0.849 (ID) using the DME approach applied to 
hypoglycaemia rates of 3.9 and 0.4 events/week respectively. Using the PED approach 
discounted QALE was reduced by 22.96 (IGD) and 2.355 (ID). The PED approach resulted 
in a QALE prediction less than zero for IGD. ConClusions: Failure to adequately 
accommodate the relationship between hypoglycaemia frequency and utility within 
health economic evaluations may lead to misleading predictions and estimates of 
QALE that lack face validity; particularly when hypoglycaemia rates are high.
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objeCtives: End-stage renal disease (ESRD) poses a significant burden to both 
patients and healthcare systems. In patients with type 2 diabetes mellitus (T2DM) 
improvements in the management of cardiovascular (CV) risk factor management 
has reduced CV specific morbidity and mortality. Consequently, as patients live 
longer with T2DM it is likely that the incidence and prevalence of renal disease will 
increase over time. The objective of this study was to externally validate the renal 
specific disease progression rates used in the IMS CORE diabetes model (CDM) to 
the UKPDS 64 and UK clinical practice. Methods: A Markov state transition model 
was developed to predict the progression of renal disease populated with transition 
probabilities from the CDM (derived from US and Israeli published studies) and the 
UKPDS 64 nephropathy model. Time to ESRD and the cumulative percentage with 
ESRD at 10, 20 and 40 years, or lifetime, whichever occurred first, were compared and 
contrasted with published ESRD projections derived from UK clinical practice data 
(The Health Improvement Network [THIN]). Baseline patient characteristics were 
taken from published THIN data. Results: For T2DM subjects aged 51 with mean 
systolic blood pressure of 139mmHg and HbA1c of 8% the predicted time to ESRD 
was 23.39 and 24.02 years when using CDM and UKPDS 64 transition rates, respec-
tively. The cumulative incidence of ESRD at 10, 20 and 40 years was 2.21%, 10.04% and 
24.96% respectively with CDM and 3.29%, 9.88% and 26.73% with UKPDS 64. Predicted 
20-year cumulative risk of ESRD from THIN varied between 5-18% dependent upon 
cohort characteristics, consistent with output from both CDM (10.04%) and UKPDS 
(9.88%). ConClusions: This study provides evidence of the consistency between 
approaches to modelling renal disease employed by the CDM and reported from 
UKPDS; furthermore, both approaches provide estimates consistent with data from 
UK clinical practice.
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objeCtives: Remission, the spontaneous resolution of symptoms among patients, 
is one of the characteristics of chronic spontaneous (or idiopathic) urticaria (CSU/
CIU). Limited literature currently exists regarding remission rates among chronic urti-
caria (CU) or CSU/CIU patients and available estimates vary. Due to the requirements 
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objeCtives: To compare cost-effectiveness of delayed-release dimethyl-fuma-
rate (DMF; also known as gastro-resistant DMF) vs. pharmacological alternatives 
indicated for the first-line treatment of relapsing-remitting multiple sclero-
sis (RRMS), adopting the perspective of the Italian National Healthcare Service 
(NHS). Methods: A cost-effectiveness model was used to evaluate costs and 
outcomes of patients treated with DMF, vs. interferon beta-1a intramuscular (IFN 
beta-1a, IM), interferon beta-1a subcutaneous, at two different doses (IFN beta-1a, 
SC 22mcg and SC 44mcg), interferon beta-1b subcutaneous (IFN beta-1b, SC), glati-
ramer acetate subcutaneous (GA), and oral teriflunomide (TER). The Markov model 
used for the analysis evaluated the effects of disability progression, relapses, and 
treatment-related adverse events, on direct healthcare costs and quality adjusted 
survival of RRMS patients, over a 50-year (lifetime) horizon. Comparative effec-
tiveness and safety data used in the model were derived from a mixed treatment 
comparison. All unit tariffs and costs were adapted to the Italian setting. Results: 
Lifetime direct healthcare costs associated with DMF were € 276,500 per patient, 
yielding to 19.50 life-years (LYs) and 6.55 quality-adjusted LYs (QALYs). The incre-
mental cost-effectiveness ratio (ICER) of DMF vs. the analyzed alternatives ranged 
between € 11,272 per QALY gained (DMF vs. IFN-beta 1b SC) to € 23,409 per QALY 
gained (DMF vs. TER). DMF was dominant vs. IFN-beta 1a SC 44mcg. Probabilistic 
sensitivity analysis conducted on both clinical and economic data showed that like-
lihood for DMF of being cost-effective, using a willingness-to-pay (WTP) threshold of 
€ 50,000 per QALY gained, was between 70.0% (DMF vs. TER), and 92.8% (DMF vs. IFN-
beta 1b, SC). ConClusions: At the current pricing and reimbursement conditions 
established by the Italian NHS, DMF represents a cost-effective option vs. first-line 
treatments indicated in RRMS. ICER associated with DMF is much lower than the 
€ 50,000 per QALY gained value, the cost-effectiveness of dialysis, commonly used 
in Italy as benchmark to issue positive funding recommendation.
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objeCtives: We demonstrate an approach to assess the impact of uncertainty in 
risk predictions on health-economic outcomes in risk-stratified prevention strate-
gies, illustrated for preventive statin treatment based on 10-year coronary heart 
disease (CHD) risk predicted by the Framingham risk score (FRS). Methods: We 
refitted the FRS to three random samples of increasing size (N= 2,500, N= 1,000, 
N= 500) from a population-based cohort. A Markov decision-analytic model was 
used to simulate cohorts with preventive statin treatment in high-risk (FRS≥ 20%) 
individuals (ATPIII guideline). This treatment threshold was incrementally lowered 
to T= 0.0% with 0.5% decrements. Using the cohort the distribution of individuals 
over the low (< 0.5T%), intermediate (0.5T%-T%), and high (≥ T%) risk category and 
corresponding observed CHD-risks were calculated. The Net Health Benefit (NHB) 
(willingness-to-pay of $50,000/QALY) was calculated and uncertainty in outcomes 
was assessed with probabilistic sensitivity analysis. The NHB for each 0.5% risk 
category was calculated to assess the impact of risk prediction uncertainty on asso-
ciated uncertainty in NHB. Results: Prediction model performance was fair in all 
samples (c-statistic: 0.70-0.75). Prediction uncertainty resulted in probabilities of 
incorrect treatment decisions of up to 0.4 (N= 2,500) and 0.5 (N= 500) for risk around 
T= 20.0%. The NHBs per risk category ranged from -0.031 for a predicted risk of 
[3.5%;4%] to 0.020 for [10.0%;10.5%] in men and from -0.067 at [0.0%;0.5%] to 0.045 
for [2.0%;2.5%] in women. The NHB was positive for predicted risks > 12.5% in men 
and > 11.5% in women. For individuals with predicted risks < 7.5% or > 20%, in 95% 
of PSA simulations the NHB was negative or positive, respectively. ConClusions: 
Risk-stratified prevention is increasingly recommended. While uncertainty in risk 
predictions may lead to incorrect treatment decisions, associated impact on long-
term health-economic outcomes is unknown. Assessing this impact can guide 
studies aiming to improve prediction models by focusing on individuals for which 
improvement may actually improve health-economic outcomes.
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objeCtives: To identify and summarise challenges to the economic model-
ling of macular oedema due to retinal vein occlusion (RVO) and diabetic macu-
lar oedema (DMO). Methods: National Institute for Health and Care Excellence 
(NICE) technology appraisals (TAs) for RVO and DMO published before 1 June 2015 
were reviewed to identify areas of uncertainty in submitted economic models. 
Evaluations were compared to assess whether, over time, these uncertainties have 
been addressed. Results: Three completed NICE TAs were identified for RVO and 
two for DMO. The main area of uncertainty identified related to whether patients 
would be treated in their better-seeing eye (BSE), worse-seeing eye (WSE) or both 
eyes (bilateral), and consequently how this should be modelled. This had implica-
tions for the appropriate application of utility estimates for patients treated in the 
BSE, WSE or bilaterally and for the classification of patients as blind. Blindness is 
associated with high costs and low quality of life, which were incorrectly accounted 
for in one-eye models. Other areas of uncertainty included the relevance of the 
